Inhibition and Reversal of Myogenic Differentiation by Purine-Based Microtubule Assembly Inhibitors  by Perez, Omar D et al.
Chemistry & Biology, Vol. 9, 475–483, April, 2002, 2002 Elsevier Science Ltd. All rights reserved. PII S1074-5521(02)00131-X
Inhibition and Reversal of Myogenic Differentiation
by Purine-Based Microtubule Assembly Inhibitors
synthesized a targeted chemical library of purine-based
kinase inhibitors (2,6,9-trisubstituted purines) around
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inhibitor (Figure 1A) [6–8].1Department of Chemistry
The activity of the compounds was assayed in C2C12University of California, Berkeley
muscle cells—a mouse cell line that retains the abilityBerkeley, California 94720
to differentiate in culture. Myogenic differentiation re-2 Department of Chemistry
quires a cell cycle arrest to induce expression of theThe Scripps Research Institute
proper phenotype. Inhibition of cell cycle progression10550 N. Torrey Pines Road
induces myogenic differentiation [9, 10]. The screeningSan Diego, California 92037
of the purine-based library sought compounds that pro-3 Genomic Institute of the Novartis
moted or inhibited the terminal differentiation of C2C12Research Foundation
myogenic precursors. Using such a screen, we pre-3115 Merryfield Road
viously identified myoseverin as a novel purine tubulinSan Diego, California 92121
binding molecule that augmented the terminal differenti-
ation of muscle cells and induced expression of immu-
nomodulatory and stress-responsive genes [1].
Summary We report here the reversal and inhibition of terminal
myogenic differentiation by exogenous application of
Using a muscle cell differentiation screen, we have myoseverin at low micromolar concentrations. Treat-
identified myoseverin from a 2,6,9-trisubsituted purine ment of myoseverin reverted multinucleated myotubes
library as a purine-based microtubule binding mole- to a mononuclear state that was responsive to growth
cule [1]. Structure-activity relation studies of myosev- factors and proliferation. Mononuclear cells derived
erin identify positions N2 and N6 to be critical for inhib- from terminally differentiated muscle cells (referred to
iting muscle differentiation. Inhibition of microtubule as myotubes) by treatment with myoseverin were also
polymerization induced the reversion of terminally dif- responsive to differentiation conditions and retained the
ferentiated myotubes to mononucleated cells that capability to form multinucleated tubes after treatment.
were responsive to both growth and differentiation Functional characterization of the cellular effects identi-
conditions, without any observable cytotoxicity. Com- fies the downregulation of differentiation markers Myf5,
MyoD, and myosin heavy chain, with a concomitantparison of myoseverin derivatives to taxol, vinblastine,
upregulation of cell cycle proteins cyclin A and CDK2nocodazole, and colchicine identify myoseverin’s ef-
after myoseverin treatment and addition of growth me-fect as being selectively reversible in addition to lack-
dia. These cells in this state can also be induced toing the cytotoxic effects of these non-purine-based
differentiate for a second time if they are placed undermicrotubule-disrupting molecules. Myoseverin, as a
differentiation conditions rather than growth conditions.purine-based microtubule inhibitor, reverted terminal
Structure-activity relation (SAR) studies of synthesizedmuscle-differentiated cells to a state that was respon-
myoseverin derivatives identify positions N2 and N6 assive to environmental cues. These results suggest that
critical for the bioactivity of myotube disassembly. Anal-myoseverin may have applications in muscle regener-
ysis of derivatizations at position N9 identifies a struc-ation and stem cell differentiation.
tural requirement for a branched/cyclic moiety for the
reversibility of myotube formation and correlated withIntroduction
the inhibition of microtubule polymerization in vitro.
Comparison with other microtubule interfering agents,
Chemical genetic approaches have gained precedence taxol, vinblastine, nocodazole and colchicine, mediated
for both drug discovery and as tools for probing biologi- a similar myotube disassembly; however, only myosev-
cal systems [2]. The feasibility of finding bioactive mole- erin was nontoxic and reversible. Thus, it resulted in
cules for a desired phenotype has been greatly en- responsive cells that can be induced to either proliferate
hanced by the combinatorial chemistry techniques that or differentiate. These results further characterize myo-
allow the parallel synthesis of molecules on the order severin’s effect on terminal-muscle cell differentiation
of a hundred thousand or more - of which only a select and demonstrate the induction of a reversible state of
few compounds will display interesting properties in re- terminally differentiated muscle cells. Furthermore, the
lation to their biological target [3–5]. Our laboratory has noncytoxic effects displayed by myoseverin and some
of its derivatives might have useful applications for both
4 Correspondence: operez@stanford.edu muscle cell biology and muscle regeneration.
5 Present address: Department of Molecular Pharmacology, Stan-
ford University, Stanford, CA 94305. Results and Discussion
6 Present address: Department of Chemistry, New York University,
100 Washington Square East, New York, NY 10003.
Morphological and Phenotypic Characterization7 Present address: Cellomics, 635 William Pitt Way, Pittsburgh, PA
of Myoseverin’s Effect on Muscle Cells15238.
Myoseverin had been identified from a morphological8 Present address: Genentech, 1 DNA Way, South San Francisco,
CA 94080. screen with the 2,6,9-trisubstituted purine library [1]. A
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series of cell-based assays were used to categorize the
effects the purine library members would have on C2C12
cells. Although the original screen was designed to iden-
tify molecules that induced cell cycle arrest and there-
fore myogenic differentiation in the C2C12 system, the
unexpected morphological effects and lack of any observ-
able cytotoxicity of myoseverin (Figure 1B) prompted
further investigation. The screens took advantage of the
facts that muscle differentiation can be assayed mor-
phologically (Figure 1C) and that several inhibitors of
the yeast Cdk homolog were identified in the library of
purines that was screened [6, 11]. Muscle cells grown
in the presence of growth factors will remain in a prolifer-
ative single-cell state [12]. Switching the cells to a de-
prived media of growth factors induces myogenic differ-
entiation [13]. Myogenic differentiation is characterized
by the formation of multi-nucleated myotubes that result
from cell fusion and elongation. This morphological dif-
ference is readily observed with phase contrast and
immunofluorescence microscopy and is also monitored
by the expression of specific differentiated-muscle cell
markers such as myosin heavy chain, MyoD, Myf5, and
surface marker acetycholine receptor (AchR) [14–16].
Myotube Fragmentation Generates Mononuclear
Cells Derived from Multinucleated Myotubes
A dose response curve of myoseverin’s effect reported
a bioactivity for myotube disassembly for a 24 hr treat-
ment to be 11  4 M, referred to as the intracellular
concentration at which 50% of the myotubes had disas-
sembled (IC50). Immunofluorescence microscopy was
performed in order to assess how the morphological
changes observed were related to changes in cytoskele-
Figure 2. Immunofluorescence Microscopy of Myotube Structure
tal organization. Staining for tubulin revealed a uniform and Consequential Effects of Myoseverin Treatment
filamentous network of microtubule structure in the mul- (A) Terminally differentiated myotubes were stained for tubulin
tinucleated myotube (Figure 2A). Punctate AchR stain- (green), nuclei (blue), and acetylcholine receptor (red) by the use of
ing identified a terminally differentiated myotube (Figure anti-tubulin antibodies, Hoescht, or rhodamine-labeled -bungaro-
toxin, respectively. Myoseverin-treated (10M, 24 hr) (bottom panel)2A). Treatment of terminally differentiated myotubes
and untreated (top panel) myotubes are shown.with myoseverin resulted in a fragmentation of the myo-
(B) Mild permeabilization of myotubes reveals microtubule disorga-tube structure [1], and occasionally the expulsion of a
nization after the treatment of myoseverin. Myotubes were stained
single nucleus was observed with the complete disrup- as described above in the presence or absence of myoseverin (10
tion of the clustered AchR (Figure 2A). Extraction of M) at the indicated times preceeding a mild permeabilization step.
monomeric tubulin from intact cells revealed a disorga-
nized microtubule networks, suggesting a possible
mechanism for myoseverin-induced myotube disas-
sembly (Figure 2B). as a function of myoseverin treatment (10M) over time.
The decrease in nuclei count per myotube over time
is consistent with the fragmentation pattern observedInduction of Monouclear Cells Derived
from Disassembled Myotubes (Figure 3A). Interestingly, removal of myoseverin (by
thorough washing) and replenishment with differentia-to Proliferate and Differentiate
The fragmentation of myotubes was quantitated by tion media induces the mononuclear cells derived from
disassembled myotubes to differentiate over the typicalcounting the number of nuclei in myotubes, as stained
for myosin heavy chain and nuclear stain hoescht dye, 3–4 days required for normal monocyte differentiation
Figure 1. Scaffold of 2,6,9-Trisubistitued Purine Library and Cellular Effects of Myoseverin, a Library Member
(A) Structure of olomoucine, a CDK2 inhibitor.
(B) Compound library cellular effects reported as percent survival and percent DNA synthesis effect on proliferating C2C12 muscle cells
(relative to DMSO control). Cell-based assays that were used to index compound effects are described in the Experimental Procedures.
(C) Structure of myoseverin and morphological effect on terminally differentiated muscle cells as visualized by phase microscopy (10 M, 24
hr treatment, n  100).
(D) Dose response curve of myotube fragmentation to varying concentrations of myoseverin for a 24 hr period. Myotube count was defined
as 1/4 the field of view with a 40 objective lens.
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Figure 3. Morphological Assessment of Myotube Disassembly and Reformation after Myoseverin Treatment
(A) Terminally differentiated muscle cells were treated with myoseverin (10 M), and the number of nuclei per myotube was counted after
immunofluorescence staining for myosin heavy chain and nuclei. The number of nuclei/myotube is plotted as a function of time for at least
five different fields of view (n  8). Control cells were terminally differentiated muscle cells that underwent DMSO vehicle treatment.
(B) The removal of myoseverin from treated myotubes (fragmented mononuclear cells) and the addition of differentiation media induces
myotube reformation. Myoseverin-treated myotubes (10 M, 24 hr) were washed thoroughly in PBS and replenished with differentiation media.
The number of nuclei/myotube was counted as described above and plotted as a function of time. Control cells were terminally differentiated
muscle cells that underwent DMSO vehicle treatment.
(C) Myoseverin inhibits muscle cell differentiation. Proliferating muscle cells treated with myoseverin (10 M and 5 M, 24 hr) were induced
to differentiate in the presence or absence of myoseverin, and the number of myotubes was counted per day. Control cells reached full
myotube formation at day 4, in contrast with the failure of myotube formation in myoseverin-treated monocytes (n  10). Myoseverin was
replenished daily to prevent rapid turnover (our unpublished data).
(D) Removing myoseverin from monocytes that failed to differentiate under differentiation conditions allowed the cells to regain the capability
to form myotubes, as monitored by myotube count as a function of time. Myoseverin was removed from 4 day-treated monocytes and
replenished with fresh differentiation media. Control cells were terminally differentiated muscle cells (n  40).
(E) Clonal expansion of mononuclear cells derived from myoseverin-treated myotubes. Mononuclear cells derived from myoseverin-treated
myotubes (10 M, 24 hr) were washed and replenished with growth media. Cell density was monitored over time and compared to growth
media-treated myotubes.
(F) BrdU incorporation of myoseverin-treated myotubes after replenishment with growth media. DNA synthesis was monitored for myoseverin-
treated (concentrations as indicated for 24 hr period) myotubes, and nontreated cells were switched to growth media for 24 hr. Values were
made relative to cycling monocytes.
in culture (Figure 3B). This reversible effect was continu- Myoseverin-treated, myotube-derived monocytes were
also susceptible to growth factors and induced prolifera-ously repeated (up to ten times) with no observable
cellular damage to the muscle cells (our unpublished tion as detected by clonal expansion of the cellular pop-
ulation (Figure 3E) and induction of DNA synthesis (Fig-data). In the continuous presence of myoseverin, the
monocytes fail to differentiate into myotubes (Figure ure 3F). These observations indicate the significant role
the microtubule architecture has in myogenic differenti-3C), in contrast with the results when the compound
is removed for cultures treated in parallel (Figure 3D). ation and suggest that the interference of microtubule
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Figure 4. Myoseverin Effect on Microtubule
Polymerization and Expression of Differentia-
tion and Proliferation Markers
(A) In vitro microtubule polymerization assay
in the absence (control) and presence of 50
M myoseverin. Nocodazole (50 M) served
as a negative control.
(B) Immunoblot analysis of differentiation
markers (MyoD, Myf5, MHC) and proliferation
markers (cyclin A, CDK2, RhoGDi) in mono-
cytes (GM), myotubes (DM), myoseverin-
treated myotubes (10 M, 24 hr; MS), and
myoseverin-treated myotubes replenished
with growth media for 24 hr (MSGM). Equal
quantities of protein were loaded and immu-
noblotted with antibodies as indicated. Tu-
bulin served as a loading control, although
myoseverin-treated cells had slightly higher
amounts for an equivalent protein content.
assembly may be a mechanism for exogenously control- cell cycle withdrawal and the initiation of myogenesis.
ling muscle cell differentiation. The myogenic basic loop helix (bhlh) factors—MyoD,
Myf5, myogenin, and MRF4—control terminal differenti-
ation by both temporal and spatial regulation [15, 18, 19].In Vitro Assessment of Myoseverin’s Effect
Myoblast differentiation requires irreversible cell cycleon Microtubule Polymerization
withdrawal and is mediated partly by MyoD expressionFor the verification of myoseverin’s effect on microtu-
[20]. Thus, MHC, MyoD, and Myf5 markers serve asbule polymerization, an in vitro microtubule polymeriza-
differentiation markers [18]. In the presence of myosev-tion assay was performed. Purified rhodamine-labeled
erin, MHC is present, with a subsequent increase in thetubulin and 500 M GTP were introduced to 50 M
expression of both MyoD and Myf5 (Figure 4B). In themyoseverin and to 50M nocodazole, a known microtu-
terminally differentiated myotubes, the apparent de-bule depolymerizer [17]. Figure 4A shows polymerized
microtubules (control). Nocodazole was used as a nega- crease in MyoD mobility and the accompanying loss
tive control to inhibit microtubule polymerization and is of Myf5 detection (Figure 4B) could be a result of the
similar to myoseverin’s effect (Figure 4A). temporal regulation of these muscle-specific transcrip-
tion factors. However, CDK2 expression is also upregu-
lated (Figure 4B). In the presence of growth factors afterFunctional Characterization of Muscle-Specific
myoseverin treatment, the expression of differentiationDifferentiation and Proliferation Markers
markers MHC, Myf5, and MyoD is down-regulated inFor the assessment of the cell state of myoseverin-
conjunction with an upregulation of cyclin A and CDK2treated cells, immunoblot analyses were performed to
(Figure 4B). These results suggest that the myogenicmonitor the expression of myosin heavy chain, tubulin,
program is overridden in the presence of growth factorsCDK2, cyclin A, RhoGDI, MyoD, and Myf5 (Figure 4B).
Terminal differentiation of skeletal myoblasts requires after myoseverin treatment, as suggested by the upreg-
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Figure 5. Structure-Activity Relation Studies of Myoseverin Derivatives at the N2, N6, an N9 Positions and Correlation with Muscle Cell
Bioactivity and In Vitro Inhibition of Microtubule Assembly
Chemical modifications were made as described in the Experimental Procedures. Functional groups are displayed for the N2, N6, and N9
positions. The N6 position is the incorporation of a second functional group at the N6 position. IC50 values for myotube disassembly were
the intracellular concentration for which 50% of the myotubes had fragmented, relative to DMSO control-treated myotubes and defined as
stated. IC50 values for tubulin polymerization were defined from the in vitro microtubule polymerization assay. Values correspond to micromolar
concentrations and were verified in at least three independent experiments. N/A means “not available,” and “-“ means that no value was
discovered to have an effect. Compounds were tested up to 100 M.
ulation of CDK2 and cyclin A. Differentiated cells placed factor and contains several CDK phosphorylation sites
that commit it to proteolysis upon phosphorylation [21,in proliferating media do not display a similar effect (our
unpublished data). RhoGDI, which has recently been 22]. This suggests that the cell cycle machinery can
influence muscle-specific proteins needed for differenti-shown to inhibit myogenic differentiation, displays in-
creased levels after growth factor replenishment post- ation.
myoseverin treatment (Figure 4B; [21]). The underlying
mechanism by which the cells are shunted from the Structure-Activity Relationships of Chemically
Synthesized Myoseverin Derivativesmyogenic program to reenter into the cell cycle is not
clearly understood. Recently, it has been shown that Myoseverin is unique in its effects on myotubes, and
studies of analogs might shed information on the speci-MyoD can be positively regulated by serum response
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Figure 6. Analysis of the N9 Functional
Group on Cellular Effects in Myotube Frag-
mentation and Inhibition of Tubulin Polymer-
ization as Compared to Microtubule-Interfer-
ing Agents
The IC50 for myotube values for myotube dis-
assembly and the IC50 values for in vitro inhibi-
tion of tubulin polymerization were plotted
and compared to taxol, nocodazole, vinblas-
tine, and colchicine (1 M, myoseverin and
derivative compounds at 10 M). Structures
of N9 position derivatives are overlayed on
data points (isopentyl group corresponds to
myoseverin). Taxol, vinblastine, nocodazole,
and colchicine had an LD50 of 1–5 M (lethal
dose at which 50% of the cells were dead) on
muscle cells, in contrast with no observable
cytotoxicity of myoseverin or its derivatives
as tested up to 100 M.
ficity/activity of the compound. To see if it was possible for inhibition of microtubule assembly. There is an ap-
parent correlation with microtubule interference and my-to correlate a structure with the molecule’s effect,
several myoseverin derivatives were synthesized by otube disassembly, supporting the notion that microtu-
bules are implicated in maintenance of the terminallysolution phase chemistry by a Mitsunobo reaction at
N9-position and subsequent amination with p-methoxy- differentiated state of the muscle cell in vivo (Figure 6).
However, the cytotoxicity of these classic microtubule-benzylamine at the N2 and N6 positions (Figure 5; [6, 7]).
This myoseverin-analog library was rescreened in differ- interfering compounds (LD50, 1–10 M) as well as their
nonreversible effects largely contrasts the nontoxicityentiated muscle cells, IC50 values were derived for myo-
tube disassembly, and the compounds were tested for and reversibility of myoseverin and its derivatives (90%
survival tested up to 100 M). This suggests that myo-inhibition of in vitro microtubule polymerization (Figure
5). Elimination of the paramethoxy functional moieties severin (and its analogs) are strong candidates for po-
tential therapeutic drugs for the treatment of degener-on the benzyl groups or substitution at the ortho and
meta positions by methoxy groups completely abol- ated muscle tissue and can also be used as biological
tools to study myogenic differentiation.ished the bioactivity of the parent molecule in both cellu-
lar and in vitro assays (Figure 5). Derivatization of the Fluorophore-conjugated myoseverin compounds
were made to study intercellular localization of myosev-para, meta, or ortho position on the benzyl ring with
amine derivatives, halides, bulky substituents, and alkyl erin. Fluorescein-conjugated and rhodamine-conju-
gated myoseverin analogs at N9 position were cell per-chains also abolished all bioactivity (our unpublished
data). Additional substituents synthesized at the N6 or meable only to proliferating cells but failed to produce
the desired effect when the cells were induced to differ-N2 positions by the addition of functional groups simi-
larly affected the cellular activity of the compound. Thus, entiate, again illustrating the importance of the N9 posi-
tion. A biotin linker has been conjugated to the N9 posi-positions N2 and N6 of myoseverin were absolutely re-
quired for cellular activity, and any functional group tion and has been used to purify tubulin as a myoseverin
binding protein [1]; however, the chemical synthesis attested augmented all myotube bioactivity (for more than
200 derivatives synthesized). this position indicates the inaccessibility to other poten-
tially interacting protein molecules by this approach.Derivitization at position N9 yielded some promising
results. Hydrophobic substituents at the N9 position had Therefore, although tubulin may contribute to the ob-
served effect, the identity of other cellular constituentspotent inhibition of microtubule assembly (Y.-T.C.’s un-
published data); smaller alkyl substituents diminished with which myoseverin interacts may illuminate the con-
nection between the myogenic differentiation programactivity when compared to the parent myoseverin mole-
cule (isopropyl [myoseverin]	 ethyl	 methyl	 H; [Fig- and the microtubule network.
ure 5]). Larger substituents enhanced the microtubule
effect in vitro but were less active in the muscle cells Significance
(myoseverin 
 cyclopentyl 
 cyclobutyl 
 cyclohexl;
[Figure 5]). The insertion of heteroatoms into the cyclo- The major findings of the present study on C2C12
hexyl ring had similar effects to myoseverin in the muscle myogenic cells have extended the functional charac-
cell-based assays (Figure 5). terization of myoseverin and illustrate that (1) mononu-
clear cells derived from myoseverin-disassembled
myotubes are susceptible to both growth and differen-Comparison of Purine-Based Microtubule
Polymerization Inhibitors to Taxol, tiation conditions, (2) myoseverin treatment can inhibit
myogenic differentiation without promoting cellularNocodazole, Colchicine, and Vinblastine
Comparisons of myoseverin N9 derivatives to known toxicity, and (3) myoseverin depolymerizes microtu-
bules, and this effect correlates with the observedmicrotubule interfering agents such as taxol, vinblastine,
nocodazole, and colchicines was performed by plotting morphological phenotype. The results so far do not
exclude myoseverin from interacting with a target thatIC50 values for myotube disassembly against IC50 values
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with Hoechst 33258 (Sigma). Myosin heavy chain (MHC) was stainedmay be responsible either for regulating the gene ex-
with a mouse MF20 anti-MHC antibody, and tubulin was stained withpression during muscle cell differentiation or for coor-
a mouse anti-tubulin antibody (see below); a fluorescein-conjugateddinating the organization of the cytoskeletal structure
horse anti-mouse IgG (Vector Laboratories) was used as a second-
that is needed for myotube formation. The results do ary antibody. The number of nuclei (stained with Hoechst) in the
indicate that myoseverin as a novel microtubule depo- presence and absence of compound was determined from at least
five microscope fields. Acetylcholine receptor was stained withlymerization agent can be used to induce terminally
-bungarotoxin Texas red conjugate (Molecular Probes, OR; 1:100differentiated C2C12 muscle cells to proliferate and
in 1 PBS) for 15 min. Mild permeabilization to myotubes prior tomay possess pharmacological activity in the treat-
fixation was performed as described [1]. Phase contrast picturesment of skeletal muscle-associated disorders or when
were visualized with a Carl Zeiss Axioskop microscope and photo-
the regeneration of muscle cell interfaces is needed. graphed onto film. Images were visualized with a Nikon epifluores-
Additionally, the nontoxicity of these purine-based mi- cence microscope and collected with a Sony digital CCD camera.
The anti-tubulin antibody developed by Michael Klymkowsky wascrotubule-interfering agents may give them potential
obtained from the Developmental Studies Hybridoma Bank devel-applications as anti-cancer agents because typical mi-
oped under the auspices of the NICHD and maintained by the Univer-crotubule-disrupting agents such as taxol and vinblas-
sity of Iowa, Department of Biological Sciences, Iowa City, IA 52242.tine have had clinical efficacy with acceptable toxic-
ities. Immunoblotting
Whole-cell extracts were prepared by lysing the cells in buffer (50
Experimental Procedures mM Tris [pH 8.0], 150 mM NaCl, 5 mM EDTA, and protease inhibitor
cocktail tablet [Boehringer Mannheim]). Lysates were cleared of
Cell Culture insoluble material by centrifugation at 4C and 10,000 g for 10 min.
C2C12 myoblast cells (CRL 1772 stock, American Type Culture Col- Protein concentrations of lysates were determined by the Bradford
lection, Rockville, MD) were kept in a proliferating state by main- assay (Biorad, Hercules, CA). Proteins (20 g) were separated by
taining them in Dulbecco’s modified Eagle’s media (DMEM, GIBCO, electrophoresis through a 12% SDS-PAGE gel and transferred to
Grand Island, NY) and 20% fetal bovine serum (Hyclone, Logan, nitrocellulose membranes (0.2 m; Biorad). Membranes were
UT). Proliferating myoblasts were induced to differentiate into myo- blocked in buffer (1 PBS, 0.1% Tween-20, 5% nonfat dry milk)
tubes by replacement of the above serum-enriched media with se- overnight at 4C and then incubated with anti-CDK2 (Santa Cruz
rum-deficient media, DMEM, and 2% horse serum (GIBCO) for 4 Biotechnology), anti-tubulin, anti-RhoGDI, anti-MyoD, anti-Myf5,
days. Differentiated and proliferating C2C12 control cells were anti-cyclin A, or anti-myosin heavy chain (1:200 dilution in 1 PBS,
treated with 1% DMSO, which was used to solubilize the com- 0.1% Tween-20, and 2% nonfat milk) for 6 hr at 4C. After incuba-
pounds. All assays were relative to this control. tions, membranes were washed five times with 1 PBS for 20 min.
Membranes were then incubated with secondary antibody (alkaline-
phosphatase-conjugated goat anti-mouse IgG or goat anti-rabbitCell-Based Assays
IgG at 1:500 dilution; or horse peroxidase-conjugated goat anti-Cytotoxicity Assays
mouse IgG or goat anti-rabbit IgG in 1 PBS, 0.1% Tween-20, andCompound toxicity was determined against both proliferating and
2% nonfat milk; Sigma Chemicals) for 1 hr at 4C. Membranes weredifferentiated C2C12 cells via the microtiter MTT assay (Boehringer
then washed five times (with 1 PBS and 0.1% Tween-20) andMannheim, IN). Cytotoxicity was also assayed morphologically by
developed by BCIP/NBT colorimetric detection (Sigma Chemicals).the staining of cells with Trypan Blue (Sigma; MO), a dye that stains
necrotic cells (as a positive control, cells were permeabilized with
0.1% Triton X-100 in PBS). The percent cell survival index is the Microtubule Polymerization Assay
MTT value of compound-treated cells relative to the MTT value of The microtubule polymerization assay was developed by the use of
control cells. Triplicate measurements were performed per exper- rhodamine-labeled tubulin (Cytoskeleton), 500 M GTP, and 5 M
iment. Mg2 and incubated at 37C for 30 min. Rhodamine-tubulin was
Differentiation Assay incubated in the presence of the compound (50 M) or its absence
Cells were assessed morphologically by direct observation under (DMSO control 1%). Visualization was done with a Carl Zeiss Axio-
the microscope, and the number of myotubes was counted in the skop microscope and photographed onto film.
presence and absence of the compounds. A myotube is defined as
a multinucleated structure of at least 1/4 the field of view in a 40 Structure-Activity Studies
objective lens. The percent differentiation index is the number of For the correlation of the selected compound’s structure with its
myotubes after compound treatment relative to the number of myo- observed effect, specific analogs were synthesized. Extrapolation
tubes of control cells. of a general structure moiety directed synthesis to a subset classifi-
DNA Synthesis Assay cation of the 2,6,9-substituted purines. Solid phase and glycinam-
Bromodeoxyuridine (BrdU) incorporation was used to measure the ide-based synthetic techniques were used to synthesize specific
rate of DNA synthesis relative to that in control cells. Anti-BrdU- 2,6,9-substituted purines as described [6, 7]. The position of the
alkaline phosphatase and ABS substrate (Boehringer Mannheim, IN) group necessary for bioactivity of lead compounds was determined
were used for detection of BrdU after a 24 hr incorporation. Absorbance by selective removal of the groups at the different positions and a
was measured with a Spectramax plate reader at 570 nm. repeat of the cell-based bioassays. All other reagents were obtained
Apoptosis Assay from Sigma/Aldrich (St. Louis, MO) unless otherwise indicated. The
Apoptosis was monitored by the TUNEL assay (Boehringer Mann- synthesized compounds were purified by the use of preparative
heim) according to the manufacturer’s instructions. Another com- TLC and characterized by reverse-phase HPLC, 1H NMR, and high-
pound from the library served as a positive control that displayed resolution mass spectrometry. The final purity of the compounds
a characteristic apoptosis DNA ladder pattern on an agarose gel was 	98%.
(our unpublished data).
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